These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1591847)

  • 21. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S; Murawski MM
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ; Maron MS
    Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of preimplantation cardiac imaging in patients referred for a primary-prevention implantable cardioverter-defibrillator.
    Krahn AD; Hoch JS; Rockx MA; Leong-Sit P; Gula LJ; Yee R; Skanes AC; Klein GJ
    Am J Cardiol; 2008 Sep; 102(5):588-92. PubMed ID: 18721517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The implantable cardioverter-defibrillator: An update.
    Miller JD; Yousuf O; Berger RD
    Trends Cardiovasc Med; 2015 Oct; 25(7):606-11. PubMed ID: 25912255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation.
    Healy CA; Carrillo RG
    Heart Rhythm; 2015 Jul; 12(7):1565-73. PubMed ID: 25839113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
    Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
    Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiac resynchronization therapy-always with ICD?].
    Stellbrink C
    Herz; 2005 Nov; 30(7):596-600. PubMed ID: 16333584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of sudden cardiac death: from wearable to subcutaneous cardioverter defibrillator.
    Viani S; Soldati E; DI Cori A; Segreti L; Paperini L; DE Lucia R; Zucchelli G; Bongiorni MG
    Minerva Cardioangiol; 2018 Feb; 66(1):83-99. PubMed ID: 28696089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary prevention of sudden cardiac death: can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian sub-study.
    Boriani G; Biffi M; Russo M; Lunati M; Botto G; Proclemer A; Vergara G; Rahue W; Martignani C; Ricci R; Santini M;
    Pacing Clin Electrophysiol; 2006 Dec; 29 Suppl 2():S29-34. PubMed ID: 17169130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventive effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy.
    Hua W; Niu H; Fan X; Ding L; Xu YZ; Wang J; Chen K; Wang F; Zhang S;
    J Cardiovasc Electrophysiol; 2012 Nov; 23 Suppl 1():S5-9. PubMed ID: 23140347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients.
    Akhtar M; Avitall B; Jazayeri M; Tchou P; Troup P; Sra J; Axtell K
    Circulation; 1992 Jan; 85(1 Suppl):I131-9. PubMed ID: 1728496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term use of the wearable cardioverter defibrillator in patients with explanted ICD.
    Kaspar G; Sanam K; Gholkar G; Bianco NR; Szymkiewicz S; Shah D
    Int J Cardiol; 2018 Dec; 272():179-184. PubMed ID: 30121177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments in the subcutaneous ICD.
    Willcox ME; Prutkin JM; Bardy GH
    Trends Cardiovasc Med; 2016 Aug; 26(6):526-35. PubMed ID: 27079889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.